Johanna Hynninen
Adjunct professor, MD, Gynecologic oncologist
mijohy@utu.fi ORCID identifier: https://orcid.org/0000-0002-0854-7225 |
Areas of expertise
gynaecologic oncology; ovarian cancer
gynaecologic oncology; ovarian cancer
Research community or research topic
https://sites.utu.fi/ovariancancer/ https://www.deciderproject.eu
https://sites.utu.fi/ovariancancer/ https://www.deciderproject.eu
Publications
- A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer (2021)
- Cancers
(A1 Refereed original research article in a scientific journal) - Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance (2021)
- Nature Communications
(A1 Refereed original research article in a scientific journal) - Diagnostic efficiency of whole-body 18F-FDG PET/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer (2021)
- Cancer Imaging
(A1 Refereed original research article in a scientific journal) - FUNGI: Fusion Gene Integration Toolset (2021)
- Bioinformatics
(A1 Refereed original research article in a scientific journal) - Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy (2021)
- Cancer Discovery
(A1 Refereed original research article in a scientific journal) - Imaging of Tumor Hypoxia With F-18-EF5 PET/MRI in Cervical Cancer (2021)
- Clinical Nuclear Medicine
(A1 Refereed original research article in a scientific journal) - Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer (2021)
- Briefings in Bioinformatics
(A1 Refereed original research article in a scientific journal) - PRISM: Recovering cell type specific expression profiles from individual composite RNA-seq samples (2021)
- Bioinformatics
(A1 Refereed original research article in a scientific journal) - Syöpäsolujen lääkeresistenssi ja miten se voitetaan - valokeilassa munasarjasyöpä (2021)
- Duodecim
(A2 Refereed review article in a scientific journal ) - ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors (2020)
- Journal of Pathology
(A1 Refereed original research article in a scientific journal)



